De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer

PURPOSE OF REVIEW: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple neg...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasoulis, Marios-Konstantinos, Heil, Joerg, Kuerer, Henry M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Breast Cancer Management: De-Escalating Breast Cancer Care (A Chagpar, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328618/
https://www.ncbi.nlm.nih.gov/pubmed/35915668
http://dx.doi.org/10.1007/s12609-022-00453-3
_version_ 1784757762573467648
author Tasoulis, Marios-Konstantinos
Heil, Joerg
Kuerer, Henry M.
author_facet Tasoulis, Marios-Konstantinos
Heil, Joerg
Kuerer, Henry M.
author_sort Tasoulis, Marios-Konstantinos
collection PubMed
description PURPOSE OF REVIEW: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. RECENT FINDINGS: Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. SUMMARY: Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.
format Online
Article
Text
id pubmed-9328618
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93286182022-07-28 De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer Tasoulis, Marios-Konstantinos Heil, Joerg Kuerer, Henry M. Curr Breast Cancer Rep Breast Cancer Management: De-Escalating Breast Cancer Care (A Chagpar, Section Editor) PURPOSE OF REVIEW: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. RECENT FINDINGS: Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. SUMMARY: Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders. Springer US 2022-07-27 2022 /pmc/articles/PMC9328618/ /pubmed/35915668 http://dx.doi.org/10.1007/s12609-022-00453-3 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Breast Cancer Management: De-Escalating Breast Cancer Care (A Chagpar, Section Editor)
Tasoulis, Marios-Konstantinos
Heil, Joerg
Kuerer, Henry M.
De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title_full De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title_fullStr De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title_full_unstemmed De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title_short De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
title_sort de-escalating surgery among patients with her2 + and triple negative breast cancer
topic Breast Cancer Management: De-Escalating Breast Cancer Care (A Chagpar, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328618/
https://www.ncbi.nlm.nih.gov/pubmed/35915668
http://dx.doi.org/10.1007/s12609-022-00453-3
work_keys_str_mv AT tasoulismarioskonstantinos deescalatingsurgeryamongpatientswithher2andtriplenegativebreastcancer
AT heiljoerg deescalatingsurgeryamongpatientswithher2andtriplenegativebreastcancer
AT kuererhenrym deescalatingsurgeryamongpatientswithher2andtriplenegativebreastcancer

Ejemplares similares